AbbVie Inc (ABBV)vsWORK Medical Technology Group LTD Ordinary Shares (WOK)
ABBV
AbbVie Inc
$263.65
+0.04%
HEALTHCARE · Cap: $447.53B
WOK
WORK Medical Technology Group LTD Ordinary Shares
$1.83
-0.54%
HEALTHCARE · Cap: $4.81M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 637741% more annual revenue ($62.82B vs $9.85M). ABBV leads profitability with a 5.8% profit margin vs -10.9%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
WOK
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.8%
Fair Value
$147.26
Current Price
$263.65
$116.39 premium
Intrinsic value data unavailable for WOK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Grey zone — moderate risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -5.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.42 suggests the stock is reasonably priced for its growth.
Bull Case : WOK
The strongest argument for WOK centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 124.8x leaves little room for execution misses.
Bear Case : WOK
The primary concerns for WOK are Altman Z-Score, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while WOK is a turnaround play — different risk/reward profiles.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 29/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
WORK Medical Technology Group LTD Ordinary Shares
HEALTHCARE · MEDICAL DEVICES · USA
WORK Medical Technology Group Ltd is a pioneering player in the medical technology sector, dedicated to the advancement of healthcare through the research, development, and commercialization of innovative medical devices. The company's diverse portfolio is designed to tackle pressing challenges in global healthcare, underscoring its commitment to improving patient outcomes. With a strong emphasis on quality, innovation, and responsiveness to market demands, WORK is ideally positioned for sustainable growth, making it an attractive investment opportunity for institutional investors seeking exposure to transformational healthcare solutions in an evolving industry landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?